Figure 1.

Median percent reduction from baseline in monthly convulsive seizure frequency and ≥50% seizure-responder rates as reported in three randomized controlled trials of fenfluramine in patients with Dravet syndrome (From bottom to up: [36,55,56]) values with statistical comparison were documented in the text.